Outcomes in rheumatoid arthritis: incorporating the patient perspective
- 1 March 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 19 (2) , 101-105
- https://doi.org/10.1097/bor.0b013e32802bf79d
Abstract
As biologics have improved the prognosis for rheumatoid arthritis, the prioritization of outcomes has shifted. Methods of quantifying concerns of particular importance to patients as a basis for better addressing the patient perspective in treatment are being developed. This review aims first to highlight some of the recent research in more traditional outcomes and then to focus on the rapid development of patient-centered outcomes over the last several years. Clinical trials with combinations of biologics and other disease-modifying antirheumatic drugs have reported significant improvement in radiographs, inflammatory markers and joint exams in rheumatoid arthritis patients. Concomitantly, several studies have appeared in major journals, reporting that patients are emphasizing outcomes such as fatigue, return to normalcy and mental health that are less easily measured by the traditional outcomes markers. Recent studies have shown both that rheumatologist and patient approaches to achieving wellness differ and providing patients with a sense of control in reaching that state of wellness leads to better outcomes. Current research is focused on evaluating how best to measure the patient assessments and incorporate the patient voice into the clinic.Keywords
This publication has 32 references indexed in Scilit:
- Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics registerArthritis Research & Therapy, 2006
- The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis & Rheumatism, 2005
- The effectiveness of anti–tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population‐based studyArthritis & Rheumatism, 2005
- Patients' perceptions of fatigue in rheumatoid arthritis: Overwhelming, uncontrollable, ignoredArthritis Care & Research, 2005
- Unmet needs in rheumatoid arthritisArthritis Research & Therapy, 2005
- Rheumatology outcomes: the patient's perspective. A multicentre focus group interview study of Swedish rheumatoid arthritis patientsRheumatology, 2004
- Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteriaRheumatology, 2004
- The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysisArthritis & Rheumatism, 2004
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- The relationship between synovitis and erosions in rheumatoid arthritisRheumatology, 1997